home / stock / krys / krys news


KRYS News and Press, Krystal Biotech Inc. From 02/20/24

Stock Information

Company Name: Krystal Biotech Inc.
Stock Symbol: KRYS
Market: NASDAQ
Website: krystalbio.com

Menu

KRYS KRYS Quote KRYS Short KRYS News KRYS Articles KRYS Message Board
Get KRYS Alerts

News, Short Squeeze, Breakout and More Instantly...

KRYS - Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024

PITTSBURGH, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, will report its fourth quarter and full year 2023 financial results on Monday, February 26, 2024, prior to the open of U.S. mark...

KRYS - Krystal Biotech, Candel, Edgewise gain after FDA fast track tags

2024-02-13 08:37:05 ET More on Candel, Edgewise, etc. Edgewise: DMD Data In The First Half Of 2024 Could Lead To Additional Testing Krystal Biotech's Vyjuvek Impresses Early On, Bolsters Prospects Krystal Biotech added to Evercore’s Tactical Outperform list on...

KRYS - Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung

• FDA clears IND and Phase 1 (KYANITE-1) clinical trial expected to be initiated in 1H 2024 PITTSBURGH, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the U.S...

KRYS - Learn to Evaluate (KRYS) using the Charts

2024-02-10 19:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

KRYS - Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa

• Initial clinical data suggest the potential of B-VEC to treat lesions in the eye of DEB patients and additional applications of Krystal’s HSV-1 platform to treat ocular diseases • Repeat administration of B-VEC eyedrops was well tolerated and associated with fu...

KRYS - Investors growing more bullish on SMID cap biotech stocks

2024-02-04 17:16:46 ET More on Alnylam Pharmaceuticals, Fusion Pharmaceuticals, etc. Merus Stock: Rally Seems Overdone Alnylam's Huge Opportunity Merus: (Maybe) Building A Better Bispecific Regeneron eyes Wegovy combo to improve quality of weight loss ...

KRYS - Krystal Biotech added to Evercore's Tactical Outperform list on drug launch

2024-02-02 11:28:52 ET More on Krystal Biotech Krystal Biotech's Vyjuvek Impresses Early On, Bolsters Prospects Krystal Biotech Inc. (KRYS) Q3 2023 Earnings Call Transcript Goldman starts Krystal Biotech at buy, cites Vyjuvek launch Seeking Alpha’s Qua...

KRYS - Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference

PITTSBURGH, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Guggenheim 6 th Annual Biotechnology Conference, which takes place in Ne...

KRYS - Objective long/short (KRYS) Report

2024-01-31 04:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

KRYS - Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®

PITTSBURGH, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, toda...

Previous 10 Next 10